Latest stories

  • in

    Immunotherapy response in advanced melanoma influenced by prior treatments: Study

    Immunotherapy response in advanced melanoma influenced by prior treatments: Study

    When a patient is diagnosed with advanced melanoma, they usually are treated with immune therapies like anti-PD-1 blockade and anti-CTLA-4 blockade, in combination or alone. By blocking different proteins that diminish the effectiveness of T cells, these checkpoint inhibitors enhance the body’s immune response to cancer. Research led by scientists at UCLA Jonsson Comprehensive Cancer […] More

  • in

    Novel immunotherapy delivery approach benefits some melanoma patients with leptomeningeal disease

    Novel immunotherapy delivery approach benefits some melanoma patients with leptomeningeal disease

    A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center. […] More

  • in

    New immunotherapy agent safe and promising against high-risk prostate cancers

    New immunotherapy agent safe and promising against high-risk prostate cancers

    Enoblituzumab, a monoclonal antibody drug works by binding to a protein called B7-H3 that is overexpressed on prostate cancer cells and believed to impede the immune system’s ability to attack cancer cells. The new drug is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to […] More